Effects of Paroxetine on Cardiovascular Function in Septic Patients
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Septic Shock, Sepsis
In brief
It is known that septic shock is characterized by arterial hypotension, decreased peripheral vascular resistance and hyporeactivity to vasoconstrictor agents, with NO being an important mediator of this organ dysfunction. Data in the literature have shown that hyporeactivity to catecholamines is associated with a decrease in the density of α and ß receptors in the aorta and heart, respectively, as well as an increase in GRK2 levels and that NO contributes to the increase of this kinase in sepsis . Based on this, it is hypothesized that cardiac dysfunction and decreased peripheral vascular resistance observed in sepsis may result from an increase in GRK2 activity and/or expression and its inhibition may be a relevant therapeutic target in septic shock patients. Based on this line, a measurable clinical benefit of paroxetine through the regulation of GRK2 expression in patients with septic shock is postulated.
Key facts
- Study ID
- NCT05725837
- Run by
- Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude
- People needed
- 92
- Starts
- 2023-06-10
- Expected to finish
- 2025-04-15
- Last updated by the study team
- 2025-01-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patient over 18 years of age;
- Patient diagnosed with septic shock for less than 48 hours and using a minimum dose of noradrenaline (0.01 mcg/kg/min);
- Patients and/or legal guardians who consented to participate in the study through the free and informed consent term before randomization.
You may not qualify if…
- Pregnant women;
- Patients with inability to use the gastrointestinal tract;
- Patients with known intolerance to paroxetine and/or fluoxetine;
- Patients on concomitant use of medications that may potentiate the occurrence of serotonin syndrome (tramadol, citalopram, escitalopram, sertraline, desvenlafaxine, venlafaxine, duloxetine, sibutramine, bupropion, amitriptyline, nortriptyline, lithium);
- Patients in end-of-life care or with an expected survival of less than 24 hours at the time of eligibility
Where it is running
- Hospital Maternidade São José de Colatina — Colatina, Espírito Santo, Brazil (enrolling)
- Hospital São José — Criciúma, Santa Catarina, Brazil (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.